Lilly rose about three points, Intuitive Surgical basically didn't move, Impact Therapeutics-B fell more than two points — large Pharma + large medical device companies held steady, while Hong Kong small-cap Biotech stocks followed the sentiment downward.
Is it the large pharma earnings + GLP-1 main theme and Hong Kong Biotech liquidity issues widening the valuation gap, or are funds on the two sides completely out of sync?
It looks more like the former is already self-consistent — Lilly's GLP-1 continues to perform well, Intuitive Surgical's robotic surgery capex growth is stable, while Hong Kong Biotech stocks without clear clinical milestones see their volatility amplified by funding issues. The more than two-point drop in Impact Therapeutics looks more like a passive decline, not due to negative news.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
